• 15 Jan 2026
• Admin
• News Article

Revance and Teoxane Secure FDA Approval for RHA® Dynamic Volume in Midface Aesthetics

Revance and Teoxane have received US FDA approval for RHA® Dynamic Volume for cheek augmentation and correction of age-related midface contour deficiencies.

The approval applies to adults aged 22 years and older. Formerly known as RHA® 4 Mepi, the product will officially launch under its new name in Q1 2026.

What This Approval Covers?

RHA® Dynamic Volume is now approved for:

• Cheek augmentation
• Correction of age-related midface contour deficiencies
• Use in adults aged 22 and above

This expands the clinical utility of the Teoxane RHA® Collection in the US market.

Designed for Dynamic Facial Movement

RHA® Dynamic Volume is engineered to provide volume while adapting to facial motion. Key product characteristics include:

• High dynamic strength and stretch
• Long-lasting volume and projection
• Structural integrity during facial expressions

The filler is powered by Preserved Network Technology (PNT), a gentle, heatless crosslinking process that preserves hyaluronic acid structure.

Leadership Perspective from Revance

Revance CEO Nadeem Moiz highlighted the strategic importance of the approval. He noted that this marks the second major advancement for the Teoxane RHA® Collection in recent months, following the introduction of mepivacaine.

The new indication allows Revance to address a broader range of patient needs in facial aesthetics.

Phase III Clinical Data at a Glance

The FDA approval is supported by a 52-week Phase III clinical trial program. Study design highlights:

• Prospective, randomized, double-blinded
• Multicenter, head-to-head comparison
• Comparator: Juvéderm® Voluma® XC

Key clinical outcomes:

• Comparable effectiveness to Voluma®
• Fewer treatment sessions and touch-ups
• Over 94% of patients reported natural-looking results
• No perception of restricted facial movement up to one year

Patients also reported improvements in:

• Cheek attractiveness
• Youthfulness and smoothness
• Facial contour and symmetry

Modern Midface Treatment Approach

During the trial:

• 75% of patients were treated in both superficial and deep fat layers
• The approach focused on balanced, efficient volume restoration

This reflects a contemporary strategy for addressing midface volume loss.

Safety Profile

RHA® Dynamic Volume demonstrated a favorable safety profile.

Notable findings include:

• No serious treatment-related adverse events
• No late-onset adverse events
• No granulomas or delayed inflammatory reactions

Teoxane’s Multilayering Technique™

The approval introduces broader adoption of the Teoxane MLT Multilayering Technique™ in the US.

This technique:

• Uses a single adaptable gel
• Targets multiple tissue depths
• Restores volume while maintaining facial harmony

It emphasizes anatomical precision and avoidance of high-risk vascular zones.

Expert View from the Clinic

Dr. Steven Dayan, a double board-certified facial plastic surgeon, called the approval a major advancement for the aesthetics industry.

He emphasized the strength of the clinical results and the value of tailored midface treatments for patients.

Why This Matters for the Aesthetics Market?

This FDA approval strengthens Revance’s aesthetics portfolio and deepens Teoxane’s footprint in the US.

It also reflects a broader shift toward:

• Dynamic, movement-adaptive fillers
• Fewer touch-ups with sustained outcomes
• Natural-looking aesthetic results

For clinicians and patients, RHA® Dynamic Volume adds a flexible, data-backed option for midface rejuvenation.